Opyl Ltd (OPL) - Total Assets
Based on the latest financial reports, Opyl Ltd (OPL) holds total assets worth AU$384.82K AUD (≈ $272.29K USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Opyl Ltd for net asset value and shareholders' equity analysis.
Opyl Ltd - Total Assets Trend (1996–2024)
This chart illustrates how Opyl Ltd's total assets have evolved over time, based on quarterly financial data.
Opyl Ltd - Asset Composition Analysis
Current Asset Composition (June 2024)
Opyl Ltd's total assets of AU$384.82K consist of 94.2% current assets and 5.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$374.65K | 91.0% |
| Accounts Receivable | AU$7.71K | 1.9% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$17.98K | 4.4% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Opyl Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OPL market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Opyl Ltd's current assets represent 94.2% of total assets in 2024, an increase from 52.7% in 1996.
- Cash Position: Cash and equivalents constituted 91.0% of total assets in 2024, up from 51.4% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is cash and equivalents at 91.0% of total assets.
Opyl Ltd Competitors by Total Assets
Key competitors of Opyl Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alcidion Group Ltd
AU:ALC
|
Australia | AU$115.63 Million |
|
DocCheck AG
XETRA:AJ91
|
Germany | €53.98 Million |
|
TRELLUS HEALTH LS -0006
F:85Q
|
Germany | €9.22 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$17.99 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$23.68 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
|
Oneview Healthcare Plc
AU:ONE
|
Australia | AU$15.49 Million |
Opyl Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 0.89 | 1.22 |
| Quick Ratio | 0.53 | 0.89 | 1.22 |
| Cash Ratio | 0.47 | 0.82 | 0.00 |
| Working Capital | AU$-330.41K | AU$-80.83K | AU$106.62K |
Opyl Ltd - Advanced Valuation Insights
This section examines the relationship between Opyl Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 133.28 |
| Latest Market Cap to Assets Ratio | 11.71 |
| Asset Growth Rate (YoY) | -42.0% |
| Total Assets | AU$411.60K |
| Market Capitalization | $4.82 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Opyl Ltd's assets at a significant premium (11.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Opyl Ltd's assets decreased by 42.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Opyl Ltd (1996–2024)
The table below shows the annual total assets of Opyl Ltd from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | AU$411.60K ≈ $291.23K |
-41.99% |
| 2023-06-30 | AU$709.58K ≈ $502.07K |
-27.54% |
| 2022-06-30 | AU$979.22K ≈ $692.86K |
-60.87% |
| 2021-06-30 | AU$2.50 Million ≈ $1.77 Million |
+167.41% |
| 2020-06-30 | AU$935.77K ≈ $662.12K |
+183.43% |
| 2019-06-30 | AU$330.15K ≈ $233.60K |
-83.77% |
| 2018-06-30 | AU$2.03 Million ≈ $1.44 Million |
+223.44% |
| 2017-06-30 | AU$628.78K ≈ $444.90K |
-74.23% |
| 2016-06-30 | AU$2.44 Million ≈ $1.73 Million |
+80.76% |
| 2015-06-30 | AU$1.35 Million ≈ $955.18K |
-77.28% |
| 2014-06-30 | AU$5.94 Million ≈ $4.20 Million |
-31.01% |
| 2013-06-30 | AU$8.61 Million ≈ $6.09 Million |
-16.19% |
| 2012-06-30 | AU$10.27 Million ≈ $7.27 Million |
-34.51% |
| 2011-06-30 | AU$15.69 Million ≈ $11.10 Million |
+818.04% |
| 2010-06-30 | AU$1.71 Million ≈ $1.21 Million |
+314.48% |
| 2009-06-30 | AU$412.32K ≈ $291.74K |
-99.56% |
| 2008-06-30 | AU$93.76 Million ≈ $66.34 Million |
+16.93% |
| 2007-06-30 | AU$80.19 Million ≈ $56.74 Million |
+48.96% |
| 2006-06-30 | AU$53.83 Million ≈ $38.09 Million |
+264.38% |
| 2005-06-30 | AU$14.77 Million ≈ $10.45 Million |
-20.74% |
| 2004-06-30 | AU$18.64 Million ≈ $13.19 Million |
+72.21% |
| 2003-06-30 | AU$10.82 Million ≈ $7.66 Million |
+4.61% |
| 2002-06-30 | AU$10.35 Million ≈ $7.32 Million |
+7.72% |
| 2001-06-30 | AU$9.61 Million ≈ $6.80 Million |
-0.67% |
| 2000-06-30 | AU$9.67 Million ≈ $6.84 Million |
+36.08% |
| 1999-06-30 | AU$7.11 Million ≈ $5.03 Million |
+9.32% |
| 1998-06-30 | AU$6.50 Million ≈ $4.60 Million |
+2.03% |
| 1997-06-30 | AU$6.37 Million ≈ $4.51 Million |
-5.96% |
| 1996-06-30 | AU$6.77 Million ≈ $4.79 Million |
-- |
About Opyl Ltd
Pathkey.AI Ltd engages in the development of digital tools that enhance healthcare experience for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs for pharmaceuticals, medical devices, alternative therapies, and novel conditions. It also provides TrialGen, an AI-powered tool strea… Read more